MRI in High-Grade Glioma Patients Undergoing Chemoradiation

Description

The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.

Conditions

High Grade Glioma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.

A Feasibility Study of Interim PET-MRI in High-grade Glioma Patients Undergoing Chemoradiation

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

Condition
High Grade Glioma
Intervention / Treatment

-

Contacts and Locations

Winston-Salem

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States, 27157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pathologically confirmed diagnosis of high grade glioma (grade III or IV) or WHO grade II glioma, IDH wildtype (molecular glioblastoma multiforme \[GBM\]).
  • * ≥18 years of age.
  • * ECOG performance status of 0 to 3
  • * Anticipated to receive 6 weeks of chemoradiation
  • * Does not speak or read English
  • * Unable to participate in cognitive testing due to aphasia or other severe cognitive impairment as determined by the PI, or Dr. Cummings or her designee.
  • * Unable to give informed consent
  • * Past medical history of any kind of dementia or diagnosed with mild cognitive impairment prior to diagnosis with their brain tumor
  • * Unable to safely fast for 8 hours prior to bloodwork or 6 hours prior to PET scan
  • * Currently taking cognition-enhancing medications including:
  • * Donepezil
  • * Memantine
  • * Armodafinil
  • * Methylphenidate
  • * Pregnant or nursing mothers.
  • * Patients taking blood thinners will be excluded from the optional Lumbar Puncture only, they are eligible for participation in the main study-provided they meet inclusion/exclusion criteria

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Christina Cramer, MD, PRINCIPAL_INVESTIGATOR, Wake Forest Baptist Comprehensive Cancer Center

Study Record Dates

2024-12